Critical Issues Need Answers:
Providing Best Options for Myeloma Treatments in 2014
Friday, Dec. 5, 2014
San Francisco, California
Click here for more information and to register for this event
|Format and Topics:
The Symposium will have a unique program format that includes "Point & Counterpoint" presentations and interactive case discussions to promote audience participation.
Each point-counterpoint session will begin with an initial Clinical Question and why it is a clinical challenge followed by the presentation of 2 alternative views on the indicated issue.
Summaries of Key Relevant Data
Plus a follow up discussion open to all symposia faculty will be part of each session.
Symposium Topics Are:
- When to Treat Patients With Smoldering Myeloma
- Assessing Response and Minimal Residual Disease Following Induction Therapy
- Incorporating Maintenance Therapy into Treatment Strategies
- Best Choices of Salvage Therapy in Relapsed/Refractory Myeloma
Speaker 1: Brian G.M. Durie, MD (Program Director)
Institution: Cedars-Sinai Outpatient Cancer Center, Los Angeles, California
Speaker 2: Shaji Kumar, MD
Institution: Mayo Clinic, Rochester, MN
Speaker 3: Ola Landgren, MD, PhD
Institution: Memorial Sloan Kettering, New York, NY
Speaker 4: Bruno Paiva, MD
Institution: University of Navarra, Pamplona, Spain
Speaker 5: Antonio Palumbo, MD
Institution: University of Turin, Turin, Italy
Speaker 6: S. Vincent Rajkumar, MD
Institution: Mayo Clinic College of Medicine, Rochester, Minnesota
At the conclusion of the activity, participants should be able to:
- Incorporate emerging data into the management algorithm for patients with high-risk smoldering multiple myeloma
- Assess response and minimal residual disease to make informed treatment decisions for patients with multiple myeloma in the transplant?eligible and –ineligible settings
- Choose optimal maintenance therapy for patients with multiple myeloma to extend and improve outcomes
- Integrate current best practices for salvage therapy in patients with relapsed/refractory multiple myeloma to improve responses
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC. The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians.
The Annenberg Center for Health Sciences at Eisenhower designates this live activity for a maximum of 4.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Conflicts of Interest
The Annenberg Center for Health Sciences at Eisenhower (Annenberg Center) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
This activity is supported by Bristol-Myers Squibb, Celgene Corporation, Millennium Takeda, Onyx, and The Binding Site.
Jointly sponsored by the International Myeloma Foundation, Annenberg Center for Health Sciences at Eisenhower, and Clinical Care Options